[Clinical analysis of liver non-Hodgkin's lymphoma].
OBJECTIVE
Incidence of liver non-Hodgkin's lymphoma (NHL) is increasing. This study was to explore clinical features, diagnosis, treatment, and prognosis of liver NHL.


METHODS
Records of 45 patients with liver NHL treated in our hospital from Jan. 1998 to May 2002, 9.6% of all NHL patients treated in the same period, were retrospectively analyzed with statistic software package of SPSS10.0.


RESULTS
Of 45 patients, 32 were male,and 13 were female, the median age was 50 years. Immunophenotyping revealed that 24 cases were T cell original, 19 were B cell original, and 2 were undefined. According to International Work Formulation (IWF), 92% of 45 patients belonged to intermediate-grade. Clinical features of liver NHL were presented with fever, jaundice, hepatosplenomegalia, and liver dysfunction. Combination treatment based on chemotherapy was the major therapy. Median survival time was 4 months, overall 1-, and 2-year survival rates were 22%, and 18%.


CONCLUSIONS
Early diagnose liver NHL is difficult, its treatment effect and prognosis are poor, combination therapy should be given as early as possible.
Zheng
Wen
W
Department of Medical Oncology, Beijing Cancer Hospital, School of Oncology, Peking University, Beijing, 100021, P.R.China. zhengwen824@sohu.com
Yong
Wei-Ben
WB
Zhu
Jun
J
Zhang
Yun-Tao
YT
Wang
Xiao-Pei
XP
Xie
Yan
Y
D000293:Adolescent; D000328:Adult; D000368:Aged; D000410:Alanine Transaminase / Q000097:blood; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D001219:Aspartate Aminotransferases / Q000097:blood; D001663:Bilirubin / Q000097:blood; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000097:blood / Q000188:drug therapy*; D016393:Lymphoma, B-Cell / Q000097:blood / Q000188:drug therapy; D008228:Lymphoma, Non-Hodgkin / Q000097:blood / Q000188:drug therapy*; D016399:Lymphoma, T-Cell / Q000097:blood / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D011241:Prednisone / Q000008:administration & dosage; D011379:Prognosis; D012189:Retrospective Studies; D015996:Survival Rate; D014750:Vincristine / Q000008:administration & dosage
D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D001663:Bilirubin; D011241:Prednisone